沙美特罗/丙酸氟替卡松粉吸入剂治疗COPD的疗效观察

Clinical observation of inhalation therapy of salmeterol/fluticasone for stable chronic obstructive pulmonary disease

目的:探讨吸入型长效β2-受体激动剂与肾上腺糖皮质激素的预混制剂沙美特罗/丙酸氟替卡松对稳定期慢性阻塞性肺疾病(COPD)患者的治疗作用。方法:对120例确诊为COPD的稳定期患者随机分为治疗组和对照组,每组60例。所有研究对象均采用综合治疗,治疗组在综合治疗基础上加用沙美特罗/丙酸氟替卡松粉吸入剂(50μg/250μg)2次·d-1吸入;对照组在综合治疗基础上单用丙酸倍氯米松吸入剂(每次1吸,剂量为250μg,3次·d-1);治疗3个月,评价治疗前后肺功能的变化,采用SGRQ对临床症状进行调查评分。结果:两组临床症状积分及肺功能指标均获得了改善;与对照组相比,治疗组临床症状积分及肺功能指标的改善更加显著(P<0.05)。结论:吸入沙美特罗/丙酸氟替卡松干粉剂能够改善重度COPD患者稳定期的肺功能和生活质量。

Objective：To investigate the therapeutic effect of inhaled long-acting β2-agonists and pre-mixed corticosteroids of salmeterol /fluticasone propionate on stable chronic obstructive pulmonary disease（COPD） patients.Methods：120 patients diagnosed as stable COPD were randomly divided into two groups,both were taken combined treatment.The treatment group（n = 60） was treated with salmeterol /fluticasone propionate powder inhalation（50 μg/250 μg）,2 times·d-1 beside combined therapy;the control group（n = 60） was treated with beclomethasone dipropionate inhalation.Treat for 3 months,evaluate the changes of lung function and SGRQ survey score before and after treatment.Results：Integration of clinical symptoms and lung function indexes of the two groups were both improved;the treatment group was significantly better than the control group（P 0.05）.Conclusion：Inhaled salmeterol /fluticasone propionate dry powder can improve lung function and life quality of stable COPD patients.